| Regulatory Story | ||||||||||||
| Go to market news section |
|
|||||||||||
|
||||||||||||
Tuesday 4 December 2012
Dechra® Pharmaceuticals PLC
("Dechra" or "the Company")
(the Company)
PDMR Shareholding
The Company was informed on 4 December 2012 that Zoe Goulding, a PDMR of the Company, yesterday exercised SAYE options over 594 ordinary shares of 1p each ("Ordinary Shares") at an exercise price of £3.0492 per share.
Following this transaction, Zoe Goulding's beneficial interest stands at 7,182 Ordinary Shares, which represents approximately 0.008 per cent. of the Company's issued ordinary share capital.
Further enquiries:
Melanie Hall, Assistant Company Secretary
00 44 1782 771100
About Dechra
Dechra is an international veterinary pharmaceutical business. Its expertise is in the development, manufacturing, distribution, sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information please visit: www.dechra.com
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.
This information is provided by RNS
 |
 |
| London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply. |
| © London Stock Exchange plc. All rights reserved |